Evotec's Neuroscience Collaboration with Bristol Myers Squibb Progresses

Evotec SE has announced significant progress in its neuroscience partnership with Bristol Myers Squibb. This ongoing collaboration aims to develop transformative treatments for neurodegenerative diseases. Such diseases currently have therapies only targeting symptom management. Evotec received a $20 million payment to advance a pre-clinical program in neurodegeneration, marking a key achievement.

The partnership began in December 2016. In 2021, Bristol Myers Squibb in-licensed EVT8683, now known as BMS-986419. It was extended in 2023, emphasizing a commitment to address the unmet medical needs in this field. Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, highlighted the strengthened collaboration and the shared mission to deliver innovative treatments for neurodegenerative conditions.